Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. 더 보기
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.92 | -24.7422680412 | 7.76 | 7.78 | 5.765 | 9955059 | 6.90610435 | CS |
4 | -2.01 | -25.6050955414 | 7.85 | 8.15 | 5.765 | 7824374 | 7.29296061 | CS |
12 | -4.36 | -42.7450980392 | 10.2 | 12.505 | 5.765 | 7123491 | 8.83893707 | CS |
26 | -2.9 | -33.180778032 | 8.74 | 12.505 | 5.765 | 6489063 | 9.29565414 | CS |
52 | -3.06 | -34.3820224719 | 8.9 | 18.33 | 5.765 | 7167073 | 10.61674325 | CS |
156 | -9.11 | -60.9364548495 | 14.95 | 18.73 | 3.21 | 5472339 | 9.10525335 | CS |
260 | -20.28 | -77.6416539051 | 26.12 | 54.2081 | 3.21 | 4028825 | 12.81519366 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관